VEGF在肺癌中的临床意义及抗血管生成药物二线治疗晚期NSCLC的任务书任务书：1.简要介绍VEGF在肺癌中的作用及其临床意义；2.分析VEGF抗血管生成药物在二线治疗晚期NSCLC中的疗效及安全性；3.探讨VEGF抗血管生成药物在二线治疗晚期NSCLC中的应用前景及存在的问题；4.提出改善VEGF抗血管生成药物治疗效果的建议。参考文献：1.N.FerraraandH.P.Gerber,“Theroleofvascularendothelialgrowthfactorinangiogenesis,”ActaHaematol,vol.106,no.4,pp.148–156,2001.2.S.H.Blackwelletal.,“RandomizedphaseIItrialofcarboplatinandpaclitaxelwitheitherlinifaniborplaceboforadvancednonsquamousnon-small-celllungcancer:resultsfromtherandomizedphaseIITEACHtrial,”J.Clin.Oncol,vol.30,no.4,pp.385–393,2012.3.W.P.PaoandJ.Chmielecki,“Rational,biologicallybasedtreatmentofEGFR-mutantnon-small-celllungcancer,”Nat.Rev.Cancer,vol.10,no.11,pp.760–774,2010.4.P.D.Leeetal.,“Sustainedneovascularregressionandimprovementinclinicaloutcomeswithtasquinimodinpatientswithmetastaticrenalcellcarcinomaandovariancancer,”J.Clin.Oncol.,vol.28,no.28,pp.38–42,2010.5.C.J.Sweeneyetal.,“EffectofVEGRblockerBrivanibonprogression-freesurvivalinadvancednon-small-celllungcancer,”Clin.CancerRes.,vol.12,no.15,pp.4716–4724,2010.6.J.A.Quinnetal.,“PhaseIItrialofG3139,aBcl-2antisenseoligonucleotide,incombinationwithcarboplatinandpaclitaxelinpatientswithadvancednon-small-celllungcancer,”Clin.LungCancer,vol.5,no.4,pp.230–236,2004.